Viva Biotech Holdings (HKG:1873)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.280
-0.050 (-3.76%)
Sep 11, 2026, 4:08 PM HKT

Viva Biotech Holdings Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,9041,7291,9872,1562,3802,104
Revenue Growth
10.10%-12.95%-7.84%-9.41%13.10%201.89%
Gross Profit
657.86655.56687.4738.43815.68650.98
Operating Income
188.83193.25229.67192.68265.98236.9
Net Income
178.03219.76167.29-116.11-528.48287.55
Earnings Per Share
0.070.090.06-0.14-0.280.08
EPS Growth
-23.53%50.00%----

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Viva Bioinnovator
138.869.3118.0930.61--
Contract Development Manufacture Organisation (CDMO) and Commercialisation Services
1,082894.111,1791,3151,4851,364
Drug Discovery Services
848.37854.72821.31866.76895.06740.47
Elimination
-165.3-28.69-32.09-56.54--
Total
1,9041,7291,9872,1562,3802,104

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,0251,089941.711,036678.57800.95
Total Debt
898.121,3311,2841,9032,8232,655
Net Cash (Debt)
126.93-241.82-342.34-866.9-2,144-1,854
Net Cash Growth
------
Net Cash Per Share
0.06-0.10-0.12-0.43-1.12-0.94

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
448.43232.23373.99383.41386.0577.83
Capital Expenditures
-146.37-121.16-190.67-187.68-249.33-565.18
Free Cash Flow
302.06111.07183.32195.73136.72-487.35
Free Cash Flow Growth
171.96%-39.41%-6.34%43.16%--

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
34.55%37.91%34.60%34.26%34.28%30.94%
Operating Margin
9.92%11.17%11.56%8.94%11.18%11.26%
Pretax Margin
13.44%18.39%14.88%-2.60%-19.30%16.53%
Profit Margin
9.35%12.71%8.42%-5.39%-22.21%13.67%
FCF Margin
15.86%6.42%9.23%9.08%5.75%-23.16%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
16.7415.5310.21--25.63
Forward PE
6.835.155.155.155.1710.88
P/FCF Ratio
7.8630.739.3210.4321.69-
PS Ratio
1.251.970.860.951.253.50